drugset / Trial / NCT02969798
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Recruiting
700 enrolled
The University of Texas Health Science Center at San Antonio
American Diabetes Association · collabAstraZeneca · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.
Timeline
- Start
- 2014-01-01
- Primary completion
- 2026-12
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Metformin | Small molecule | 2000 mg | — |
| Comparator | Pioglitazone | Small molecule | 30 mg | — |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | — |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 10 mg | — |